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The products of oxidative stress trigger chronic low-grade inflammation (pathophysiological parainflammation) process in AMD
patients. In early AMD, soft drusen contain many mediators of chronic low-grade inflammation such as C-reactive protein,
adducts of the carboxyethylpyrrole protein, immunoglobulins, and acute phase molecules, as well as the complement-related
proteins C3a, C5a, C5, C5b-9, CFH, CD35, and CD46. The complement system, mainly alternative pathway, mediates chronic
autologous pathophysiological parainflammation in dry and exudative AMD, especially in the Y402H gene polymorphism, which
causes hypofunction/lack of the protective complement factor H (CFH) and facilitates chronic inflammation mediated by C-
reactive protein (CRP). Microglial activation induces photoreceptor cells injury and leads to the development of dry AMD. Many
autoantibodies (antibodies against alpha beta crystallin, alpha-actinin, amyloid, C1q, chondroitin, collagen I, collagen III, collagen
IV, elastin, fibronectin, heparan sulfate, histone H2A, histone H2B, hyaluronic acid, laminin, proteoglycan, vimentin, vitronectin,
and aldolase C and pyruvate kinase M2) and overexpression of Fcc receptors play role in immune-mediated inflammation in AMD
patients and in animal model. Macrophages infiltration of retinal/choroidal interface acts as protective factor in early AMD (M2
phenotype macrophages); however it acts as proinflammatory and proangiogenic factor in advanced AMD (M1 andM2 phenotype
macrophages).
1. Introduction
Age-related macular degeneration (AMD) is the leading
cause of permanent, irreversible, central blindness (scotoma
in the central visual field makes impossible the following:
reading and writing, stereoscopic vision, and recognition
of colours and details) in patients over the age of 50 in
industrialized European and North American countries. Soft
drusen and/or pigmentary abnormalities are clinically visible
symptoms of early AMD. Late (or advanced) AMD occurs
in two distinct forms, and visual loss is caused by the
“geographic atrophic” death of photoreceptors and retinal
pigment epithelium (RPE) cells, the so-called dry AMD,
GA/AMD, or by formation of the choroidal neovascular
membrane (CNV), as a result of pathological angiogenesis,
the so-called exudative or wet AMD, CNV/AMD [1–3].
Hypoxia, as well as hyperactivity of the complement
system, together with the inflammatory process, leads to
disturbances in the pro/antiangiogenic balance and RPE cells
overexpression of proangiogenic vascular endothelial growth
factor (VEGF), which plays a key role in the pathogen-
esis of CNV/AMD [1, 4]. AMD is a complex degenera-
tive and progressive disease of multifactorial etiology, and
advanced age (and its related physiological cell apoptosis
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and tissue involution) and genetic predisposition are the
strongest risk factors; however, important are also other
factors such as sex and environmental influences (smoking
cigarettes, heart and vascular disorders, hypertension, dys-
lipidemia/hypercholesterolemia, diabetes, obesity, improper
diet, sedentary lifestyle, and phototoxic exposure) [1–3, 5, 6].
Despite intensive researches, the pathomechanism of AMD
has not yet been fully recognized, since the pathogenesis of
AMD is likely to involve the disruption of multiple physi-
ological pathways [7]; however, according to many authors,
inflammation and especially the complement system play
key role in the etiopathogenesis of AMD. Inflammation is
involved in both late forms of AMD, that is, in GA/AMD and
CNV/AMD [8–13].
2. Chronic Low-Grade Inflammation
(Pathophysiological Parainflammation)
Model of AMD Etiopathogenesis
2.1. General Characteristics of Normal/Pathophysiological
Parainflammation Process. The term “parainflammation,”
first proposed by Medzhitov, means tissue adaptive response
to noxious stress or malfunction and has characteristics that
are intermediate between basal and inflammatory states. It
is not a classic form of inflammation caused by exogenous
tissue injury or foreign antigen (infection). Parainflammation
is a local low-grade/subclinical immune reaction, caused by
endogenous inducers (they may not be detectable by using
common inflammatory biomarkers), to adapt tissue to harm-
ful environment and tomaintain their adequate functionality.
In other words, parainflammation is a state between healthy
homeostasis and chronic inflammation [14]. However, if the
noxious stress or malfunction is prolonged and not removed,
then parainflammation progresses into a chronic condition,
with classic well known and defined inflammatory pathways,
and leads to tissue damage [14]. Oxidative stress is considered
by many authors to be the main initial determinant for
parainflammatory responses [7–9]. Parainflammationmeans
the activation of locally resident immune cells in the first
instance and the induction of complement system, mainly its
alternative pathway, in chronic conditions [7–9].
Normal, adaptive parainflammation exists in the aging
retina under physiologic conditions, as a protective response
against low-grade noxious waste products accumulated in
Bruch’s membrane, and allows maintenance of retinal home-
ostasis [8, 9]. However, prolonged period of retina exposition
to stress and/or malfunction leads to chronic unbalanced
and uncontrolled parainflammation process, due to either
prolonged and aggressive tissue damage (caused by extreme
aging or unhealthy life style) or decreased immune system
ability to repair tissue (caused by premature aging or genetic
susceptibility) [9]. Dysregulated normal parainflammation
evolves into a chronic inflammatory response [9]. Such
“chronic abnormal inflammatory process” [15], or failure
“chronic para-inflammation” [7, 9] or “pathophysiologic
para-inflammatory response” [8], leads to chronic detrimen-
tal inflammatory reactions and immunologic events [9, 15],
promotes tissue damage, and contributes to the initiation of
AMD [9, 16, 17], as well as playing an important role in AMD
progression [9, 15].
According to many authors, AMD is not classic (reg-
ular) inflammation but is a condition of “chronic low-
grade/subclinical degree of inflammation (pathophysiologic
parainflammation)” [8, 9], which plays role in every AMD
form [18]. In the course of AMD, chronic, pathophysiological
parainflammatory process occurs in the macula and in para-
central retinochoroidal tissues and is related to the anatomy-
activity complex consisting of the outer photoreceptors, RPE
cells, Bruch’s membrane, and choriocapillaris [7–9].
Parainflammation is characteristic for tissues functionally
dependent on nonproliferative cells and characterized by very
highmetabolism [8]. Photoreceptors, RPE, and ganglion cells
are terminally differentiated (postmitotic) retinal cells, with
limited or lack of ability to regenerate [9]. Neuroretina is
a highly metabolic tissue, sensitive to noxious factors, and
constantly exposed to light stimulation, which generates large
amounts of oxidized materials [9]. The major causes of tissue
stress resulting in local triggers for parainflammation are
oxidative stress and oxidative species, that is, reactive oxygen
species (ROS) and reactive nitrogen species (RNS), oxidized
lipoproteins, advanced glycation endproducts (AGEs), and
apoptotic cells [7–9].
2.2. Characterization of Main Normal/Pathophysiological
Parainflammation Triggers. Reactive oxygen and nitrogen
species are generated during normal physiological processes.
Oxidative stress occurs when the production of ROS and
RNS accelerates, or when the mechanisms involved in their
rapid removal are impaired [9]. In the retina, the inner
segments of photoreceptors and RPE cells, both rich in
mitochondria organelles, are the main source of oxidative
and nitrative species in the pathophysiological conditions [9].
Sunlight exposure, mitochondrial respiration, phagocytosis
of the outer photoreceptors segments by RPE cells, photo-
sensitization of protoporphyrin, and lipofuscin phototoxicity,
as well as unregulated choroidal blood flow, connected
with increased fluctuations of tissue oxygen concentration,
predispose the aging macula to oxidative stress and elevated
mitochondrial ROS and RNS creation [19, 20]. ROS impair
cells function by reacting with nucleic acids, proteins, and
lipids [21]; they also induce production of proinflammatory
cytokine [22] and angiogenic signals [23] and may lead to
apoptosis of photoreceptors, RPE cells, and retinal ganglion
cells in the aging retina [24]. RNS trigger damage of proteins
and lipids [25], cause nitrosative stress in the aging retina [9],
and may induce apoptotic death of photoreceptors [26].
Oxidative and nitrative species trigger parainflammation
process directly, since oxidized or nitrated lipids and pro-
teins stimulate inflammatory responses, as well as indirectly
activating the tissue resident macrophages to express proin-
flammatorymediators [9].Moreover, RONmay alter vascular
permeability and breakdown of blood-retina barrier [27],
which promote release of proinflammatory factors [9].
2.3. Oxidized Lipoproteins. The retina, particularly the pho-
toreceptor layer rich in unsaturated lipoproteins, is readily
Mediators of Inflammation 3
susceptible to oxidation by ROS. Lipid oxidation increases
with the age and occurring oxidized low-density lipoproteins
(OxLDL) are particularly relevant to retinal parainflamma-
tion [9]. OxLDL bind to RPE cells and retinal microglia via
scavenger receptors, that is, via CD36, LDL-R, and newly
described lectin-like oxidized lipoprotein receptor 1 (LOX-
1) detected in RPE cells and in microglia [28, 29], as well
as via the CD68 receptor detected in microglia [30]. OxLDL
promote parainflammation activating lipid-laden monocytes
and macrophages to secrete cytokines (IL-8), growth fac-
tors (TNF-alpha), and matrix metalloproteinases. Immune
complexes consisting of OxLDL and antibody activate also
complement system pathway [9].
The term advanced glycation endproducts(AGEs) is a
broad term which includes various proteins and lipids
undergoing chemical reactions after exposure to sugars; their
physiological serum level is in the range of 2–10 Lg/mL and
increases with the age [31]. AGEs promote inflammation
in many general age-related diseases such as Alzheimer’s
disease, atherosclerosis, diabetes, osteoarthritis [32–34], and
AMD [35]. AGEs represent risk factor of AMD development
[36].
AGEs are a constituent of drusen [37] and accumulate in
Bruch’s membrane in the course of AMD [38].They stimulate
RPE cells to secrete different anti/proinflammatory factors,
which trigger parainflammation state in RPE cells, that is,
short-term adaptive RPE cell reaction on AGE stimulation
[39]; however chronic RPE exposure to AGE favors deregu-
lation of RPE function and leads to photoreceptors and RPE
cells degeneration and atrophy [38].
According to Lin et al., anti-inflammatory cytokines
including IL10, IL1ra, and IL9 were overexpressed and
proinflammatory cytokines including IL4, IL15, and IFN-𝛾
were overexpressed, while other proinflammatory cytokines
including IL8, MCP1, and IP10 were underexpressed with
AGE stimulation of human cultured RPE cells [39]. Upregu-
lated were also chemokine CXCL11 and viperin RSAD2 [39].
Strongly immunoreactive CXCL11 protein, associated with
drusen, mediates chemotaxis between cells in inflammatory
response.
Multifactorial antiviral protein RSAD2 is also localized in
drusen and outer retina, mediating inflammatory response,
abnormal lipid accumulation, and atherosclerosis [39].
Extracellular receptors which bind AGEs on RPE cells
include toll-like receptors (TLRs), receptors for advanced
glycation endproducts (RAGEs), and advanced glycation
endproducts receptors (AGERs). TLRs and RAGEs activate
inflammatory signals within the cells, and AGERs are impor-
tant inhibitors of these signals [39].
According to Lin et al., all the above cytokines are novel
agent (genes) associated with AMD pathogenesis and candi-
date marker of inflammatory events in the outer retina, and
modulating their activity associated with specific pathways
(NF-jB and JAK-STAT pathways) may be new therapeutic
strategy to limit RPE dysfunction and photoreceptor loss in
the course of AMD [39].
AGEs also induce secretion of proangiogenic cytokines
by RPE cells (upregulation of VEGF in RPE cells after stim-
ulation by AGEs) [40]. AGEs are endocytosis and removed
by macrophages [41]. The failure in macrophage recruitment
(see below) may lead to increased RPE exposure with AGEs
and damage retinal tissue in the pathological angiogenesis
process [39].
2.4. Soft Drusen as Clinical Symptom of Chronic, Pathophys-
iological Parainflammation Process in the Retinal/Choroidal
Interface. In the aging retina, the cumulative effect of oxida-
tive stress, endoplasmic reticulum stress, and accumulation
of RPE byproducts lead to deposition of glycoproteins, lipids,
and cellular debris, as well as creating clinically invisible basal
deposits, that is, basal laminar deposits (BLamD) and basal
linear deposits (BLinD). BLamD are accumulated between
the cytoplasmic and the basement membrane of RPE cells,
and BLinD are stored in the extracellular matrix, between
the RPE basement membrane and the internal collagen layer
of the Bruch’s membrane [42–44]. Basal deposits deepen
the lipofuscinogenesis process in RPE cells, which means
accumulation of lipofuscin (age pigment) developed from
fully or partially digested outer segments of photoreceptors,
as a result of the gradual failure of RPE liposomal enzymes
[42–44]. BLamD and BLinD with diameters of over 25–
30 𝜇m turn into clinically visible macular and perimacular
soft drusen (SD), the hallmark of early AMD, and a risk factor
for developing advanced forms of AMD during the next 5 to
10 years [45, 46], that is, GA/AMD or CNV/AMD [47–49].
Soft drusen are not only the side effect of dysfunction
and degeneration of RPE cells [5, 43, 44, 46], but they
indicate also a chronic, pathophysiological parainflammatory
process in extracellularmatrix. SD are the earliest diagnosable
byproducts of local detrimental parainflammatory process
and act as foci of chronic abnormal inflammation in Bruch’s
membrane [5, 12, 13, 37, 50]. They induceactive, nonspecific
inflammatory cells reactions [46, 51] and are biomarkers
of immune-mediated processes in RPE/Bruch’s membrane
interface [52–54].
Inflammatory etiopathogenesis of human soft drusen
confirms their content, which has been recognized during
the course of numerous histochemical studies. Soft drusen
are composed of phospholipids, glycolipids, cholesterol,
saturated and unsaturated fatty acids, carbohydrates, and
approximately 130 various kinds of proteins, amongwhich are
apolipoproteins, vitronectin, clusterin, ubiquitin, fibronectin,
integrins, extracellular matrix metalloproteinases, and their
inhibitors [13, 37, 55]. Soft drusen contain also numerous
mediators of inflammation such as C-reactive protein (CRP)
[13, 56], adducts of the carboxyethylpyrrole protein (CEP)
[57], immunoglobulins (IgG) [58], acute phase molecules
(vitronectin, amyloid P, and fibrinogen), and apolipoproteins
[59] as well as many complement-related proteins such
as complement components (C3a and C5a proteins) [60],
terminal complement complex (C5 and C5b-9 proteins) [54,
56], fluid-phase complement regulators (complement factor
H-CFH, vitronectin, and clusterin) [61], and membrane-
bound complement inhibitors (complement receptor1-CR1,
also called CD35 and membrane cofactor protein-MCP, also
called CD46) [61, 62].
Many complement-related proteins such as complement
system activation products (C3a, C5, and C5b-9 proteins),
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complement activators (CFH, CD35, and CD46 proteins),
and complement regulators have shown not only in drusen,
but also in the capillary pillars of the choroid and within
surgically removed choroidal neovascular membranes [37,
54, 62, 63], as well as in the human vitreous body [4].
2.5. Chronic Autologous Pathophysiological Parainflamma-
tion Mediated by Complement System in Retinal/Choroidal
Interface. The complement system is a specific biochemical
cascade and an integral element of inborn (not specific)
immunological response, which supports (complements)
the host antibodies ability to destroy pathogens, promotes
removal of apoptotic cells and immune complexes, and
enhances an individual adaptive immune response [64].
Its deregulation or dysfunction leads to various autologous
diseases [65, 66] and is implicated in the etiopathogenesis and
progression of AMD [63, 65]. The complement system con-
sists of more than 40 proteins and regulators synthesized by
the liver and circulating in the blood as inactive precursors or
proproteins. They act in three distinct complement pathways
activated by specific trigger.The classical pathway is triggered
by antigen-antibody complexes, the alternative pathway is
activated by binding to membranes of pathogen or host cell,
and lectin pathway is triggered by binding serum lectin to
mannose residues (polysaccharides) on microbial surfaces.
The alternative and lectin pathways are called nonspecific
immune response pathways, since they do not require the
presence of a typical pathogen and act without the presence
of antibodies.
Activation of these pathways results in a proinflammatory
response including generation of cell-killing terminal com-
plement complex (TCC), also called the membrane-attack
complex (MAC), which mediate aggressor’s cells lysis, after
the spontaneous hydrolysis of the C3 factor (classic pathway)
or theC3b factor (alternative pathway), release of chemokines
to attract inflammatory cells to the site of damage, and
enhancement of capillary permeability [63, 67, 68].
The complement system is continuously activated at
low levels in the normal eye, but intraocular complement
regulators (CFH, CD35, and CD46 proteins) tightly regulate
its spontaneous activation to maintain activity at a level
that promotes elimination of pathogens and waste products
without damaging healthy tissue, and leukocytes, lympho-
cytes, andmacrophages additionally support the complement
system in cleaning the extracellular matrix [67, 68]. With the
age, the longstanding photooxidation process and oxidized
albuminous components of lipofuscin deregulate comple-
ment system and play pivotal role in the activation of classic
and alternative pathways, which leads to the chronic immune
inflammatory process in the macula in the course of AMD
[37, 57, 69].
Oxidized components of lipofuscin, that is, isolevug-
landin, bis-retinoid pyrimidine A2E, and carboxyethylpyr-
role protein (CEP), and its adducts (generated in blood as a
result of CEP conjugation with circulating plasma albumin)
are present in lipofuscin of RPE cells, in soft drusen, and
in systemic circulation [37, 57, 69]. These strongly immuno-
genic factors constitute a target for the immune system and
stimulate the production of antibodies (CEP protein) and
endogenic, autoantibodies (CEP protein adducts) [37, 57],
which lead to autologous immune-mediated inflammation,
strong attack of both the drusen material and its own RPE
cells, cells apoptosis, and finally maculae damage [63, 67, 68].
In AMD, the complement system activation is not only
an effect, but also an evidence of local, strong, and chronic
deregulation of immune system in Bruch’s membrane and
complement system pathognomonic role has been confirmed
in both: dry AMD [13] and wet-AMD [70–73].
2.6. The Influence of Gene Polymorphism on Pathophysio-
logical Parainflammation Activity. Autologous inflammation
mediated by overactive alternative pathway is especially
strong in AMD patients with the Y402H gene polymor-
phism, since it causes hypofunction or lack of the protective
complement factor H (CFH). CFH is a serum suppressor
of alternative complement activity in plasma, in host cells
and tissue, and in sites of tissue inflammation. CFH main-
tains local homeostasis and protects macula against deep
disintegration [7]. CFH is produced locally in the eye and
accumulated in the interphotoreceptor matrix, in RPE cells
and the sub-RPE space, in soft drusen, and in the choroids
[61, 74]. CFH binds to antigen epitopes, the part of an antigen
recognized by antibodies, B cells, or T cells, and protects
against oxidative stress [75]. CFH is involved in inhibiting
the inflammatory response mediated via C3b (the alternative
pathway of complement) both by acting as a cofactor for
cleavage of C3b to its inactive form C3bi and by weakening
the active complex which is formed between C3b and factor
B [7]. CFH slows down the cascade of reactions connected
with an increase in TCC, especially within the range of
the alternative pathway [61, 76, 77], and the mutation in
CFH (Tyr402His) reduces the ability of CFH to regulate the
alternative pathway permitting it to run uncontrolled [61, 68,
74].
The CFH-Y402H gene polymorphism reduces also the
CFH affinity for C-reactive protein (CRP) and results in the
high levels of unbound CRP, which facilitate chronic inflam-
mation [78, 79]. C-reactive protein (CRP) is a nonspecific
serum biomarker for acute phase of subclinical inflammation
[80]. CRP induces innate immune response to infection
and/or tissue injury, sinceCRP activates complement directly,
via alternative pathway, and indirectly, via CRP-CFH inter-
action, which improve CFH ability to inhibit complement.
CRP may also enhance phagocytosis of macrophages, which
express CRP receptor [80]. There is a significant inverse
correlation between the CRP and CFH levels in patients
with advanced AMD and CFH gene polymorphism, which
means that high level of CRP and insufficient level of CFH
at RPE/Bruch’s membrane/choroid complex may lead to
uncontrolled complement activation and macula damage
[78]. Moreover, CRP serum level >3mg/L is related to a
double AMD risk in comparison with CRP concentration
<1mg/L [81], and elevated serum CRP level together with
homozygous CFH-Y402H polymorphism leads to 19.3 risk
ratio of AMD and to 6.8 risk ratio of AMD progression [82].
According to what is above some authors state that CRP has
a direct responsibility in macular damage via complement
mediated mechanisms, especially in cases with CFH-Y402H
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gene polymorphism, and CRP is a risk factor for developing
AMD[83, 84].However, the fullmechanismofCRP influence
on AMD is not understood [7], and some authors contradict
the relation between CRP and AMD [85, 86].
Apart from complement factor H, also other serum
suppressors of the complement system activity are important,
including the family of factor H-like proteins 1–5, C4-binding
proteins, and surface protein such as membrane decay-
accelerating factor CD55, membrane cofactor protein CD46,
and receptors of the complement system CR1, CR2, and CR3
[64, 87].
The strong support for the immunoinflammatory model
of AMD pathogenesis is the highly significant correlations
between AMD and polymorphism of genes encoding pro-
teins directly involved in the complement alternative pathway
activity. Polymorphism of genes encoding complement factor
H, complement component 3, complement factor I, and
CFH-related genes-2-4-5 increases AMD risk, and polymor-
phism of genes encoding complement factor B, complement
component 2, and CFH-related genes-1-3 reduces risk of
AMD development [88].
2.7. Chronic Pathophysiological Parainflammation Associated
with Microglial Activation in Retinal/Choroidal Interface.
Microglial cells are specialized tissue macrophages resident
in the retina and are responsible for detecting noxious stimuli
in local microenvironment [89]. Microglial activation is
triggered by different endogenous factors such as oxidized
protein and lipid, as well as AGEs [90]. In the aging retina,
microglial activation is associated with the breaking down of
the outer blood retinal barrier [9]. Activated microglial cells
(large cell body and short dendrites are morphological signs
of activation) migrate from the neuroretina into the subreti-
nal space, that is, into potential space between outer segment
of photoreceptors and the apical surface of the RPE cells
in order to digest (phagocyte) their accumulated deposits
in Bruch’s membrane [30, 91, 92]. Microglial activation and
coexisting parainflammation process allow the maintenance
of local retinal homeostasis and is a form of protective
response against low-grade noxious elements in the aging
retina [9, 93]. However, in cases of prolonged stress and/or
increased immunological responses or loss of mechanisms
of their sufficient control, chronic microglial activation and
chronic parainflammation state induce proapoptotic events
and cause photoreceptor cells injury [94]. Parainflammation
connected with microglial activation leads to the develop-
ment of dry AMD [95].
2.8. Chronic Pathophysiological Parainflammation Associated
with the Activity of Autoantibodies and Immune Complexes
in Retinal/Choroidal Interface and in the Retina. Patients
with CNV/AMD have autoantibodies to various antigens
such as alpha beta crystallin, alpha-actinin, amyloid, C1q,
chondroitin, collagen I, collagen III, collagen IV, elastin,
fibronectin, heparan sulfate, histone H2A, histone H2B,
hyaluronic acid, laminin, proteoglycan, vimentin, and vit-
ronectin systemically expressed [96]. Many of the above
proteins are the building elements of extracellular matrix,
that is, the 2–4𝜇m thick Bruch membrane [97], which acts
as a frame for the metabolically active RPE cells and a
physical barrier for their passage and that of the endothelial
vessels and regulates the diffusion of nutrient molecules
between the retina and the choroid [97]. Collagens type I
and type III (fibrillar), elastin, fibronectin, and proteogly-
cans (mainly heparan sulfate proteoglycans) are the main
structural components of internal/outer collagenous and
elastic layer of Bruch’s membrane, and collagen type IV
(nonfibrillar), laminins, and proteoglycans (mainly heparan
sulfate proteoglycans) are the main structural components
of RPE and choriocapillaris basement membranes [5]. The
presence of such numerous autoantibodies against main
structural elements of Bruch’s membrane indicates strong
immunological process in extracellular matrix, which may
facilitate penetration of neovascular membrane through
choroidal/retinal interface under neuroretina in exudative
AMD. Sera of patientswithAMD indicate also the presence of
other autoantibodies, that is, autoantibodies against aldolase
C (ALDOC) and pyruvate kinase M2 (PKM2). ALDOC and
PKM2 are enzymes associated with glucose metabolism and
are specific for dry and wet AMD. Autoantibodies against
ALDOC/PKM2 indicate activity disorders stimulated by the
immunological inflammatory condition, which in turn may
deepen the structural changes in the Bruch membrane.
According to Morohoshi anti-PKM2 IgG should serve as a
biomarker for diagnosis and prognosis of AMD [96].
Antibodies mediate inflammation by activation of the
classic pathway of complement cascade (when they bind
their cognate antigen and form immune complexes) or
by binding Fcc receptors (FccRs) on effector cells such as
macrophages [98]. The FccRI, FccRIIa, FccRIIc, FccRIIIa,
and FccRIIIb are the activating receptors, and FccRIIb is
the inhibitory receptor in humans. Activated/inhibited FccRs
activate/inhibit function of effector cells, that is, their capabil-
ity of phagocytosis, cytokine production, and degranulation
[99]. Immune complexes produce neuroinflammation in the
retina. In early AMD, formation of immune complexes in
the choriocapillaris was accompanied with upregulation of
Fcc receptors. Large number of leukocytes expressing Fcc
receptors was observed also in exudative AMD. It implicates
a possible role for antibody-mediated inflammation in early
and advanced AMD largely dependent on the presence and
activity of Fcc receptors [100].
2.9. Chronic Pathophysiological Parainflammation Associ-
ated with Choroidal Macrophages Infiltration. Leukocytes
promote endothelial cell injury and migrate through the
endothelium to other tissues. They may infiltrate the retina
and injure the macula [101]. It is favored by higher expres-
sion of intercellular adhesion molecule-1 (ICAM-1) in the
macula, as compared to the peripheral retina [102]. Elevated
white blood cell counts correlate with the presence of soft
drusen [103] and CNV/AMD [104], as well as possibly with
GA/AMD [103], which indicates the relationship of systemic
circulating, nonspecific chronic inflammatory cells with the
pathogenesis of early and advanced AMD.
Monocytes after migration from bloodstream into the
subendothelial space differentiate into mature tissue resident
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macrophages. Their recruitment into inflamed tissues medi-
ates chemokines (signaling proteins) released by damaged or
infected cells [105]. Locally producedmonocyte chemoattrac-
tant protein (MCP)-1 (CCL2) is one of the key chemokines
which regulates migration and infiltration of monocyte.
MCP-1/CCL2 interact with the chemokine receptors type 1
and 2 (CX3CR1 and CCR2, resp.) [106, 107]. Macrophages
induce granulomatous inflammatory reactions in Bruch’s
membrane [46, 51, 108]. They were found in the choroids of
AMD patients [109], in degraded areas of Bruch’s membrane
[110, 111], and in surgically excised CNV membranes [112].
Macrophages represent a broad phenotypes spectrum
and play dual role in AMD pathogenesis. Anti-inflammatory
macrophages maintain balance of waste products in the
aging Bruch membrane and remove SD and other deposits.
Proinflammatory macrophages maintain parainflammation
state of AMD lesions and promote the development of late
stages of disease [113, 114].
M1 phenotype macrophages have proinflammatory pot-
ency and induce tissue damage [113]. M2 phenotype
macrophages are less inflammatory. In early AMD, M2
macrophages act mainly as scavenger and anti-inflammatory
factor; since they digest proinflammatory agents such as
AGEs, complement complexes, oxidized membrane, and
dead cells, removal of apoptotic cell debris limits inflam-
mation through inhibiting the production of inflammatory
cytokines [113, 114]. Failure in recruitment M2 macrophages,
caused by inhibition of receptor CCR2, essential for scav-
enging deposits [115] leads to increased RPE cells expo-
sure to AGEs, which may stimulate RPE cells to secrete
proangiogenic cytokines, including VEGF [40]. In late AMD,
M2 macrophages represent proangiogenic activity and facili-
tate CNV formation, since they may express proangiogenic
cytokines (including VEGF), growth factors, and reactive
oxygen species negatively affecting the RPE and choriocapil-
laris, and they may promote proteolysis of Bruch’s membrane
as well. They also serve as scaffold for CNV development
[113, 114, 116].
3. Summary
Etiopathogenesis of AMD involves the disruption of many
physiological pathways, but chronic pathophysiological
parainflammation plays a key role in AMD development.
Normal, adaptive parainflammation process exists in the
aging retina under physiologic conditions, but unbalanced
and uncontrolled parainflammation leads to detrimental
chronic inflammatory response and causes early and advan-
ced AMD forms. Chronic pathophysiological parainflam-
mation is mediated by many factors and stimulated by com-
plement system, especially its alternative pathway, which
is carried out in Bruch’s membrane, and leads to early and
advanced, exudative AMD forms. Chronic pathophysio-
logical parainflammation connected with microglial activa-
tion carried out also in retinal/choroidal interface leads
to advanced atrophicans form of AMD. Chronic pathophy-
siological parainflammation connected with autoantibodies
and formation of immune complexes carried out in Bruch’s
membrane lead to early and advanced AMD. Chronic
pathophysiological parainflammation connected with
choroidal macrophages infiltration leads to exudative form
of AMD.
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